Silo Pharma (SILO) Income from Discontinued Operations (2020 - 2022)

Silo Pharma has disclosed Income from Discontinued Operations across 3 years of filings, most recently posting -$1163.0 for Q1 2022.

• In Q1 2022, Income from Discontinued Operations rose 98.26% year-over-year to -$1163.0; the TTM figure through Dec 2022 stood at -$1163.0 (down 100.05% YoY), while the FY2023 annual figure was -$69600.0, down 5884.52% from the prior year.
• Income from Discontinued Operations came in at -$1163.0 for Q1 2022 at Silo Pharma, down from $2.7 million in the prior quarter.
• In the past five years, Income from Discontinued Operations ranged from a high of $2.7 million in Q4 2021 to a low of -$189119.0 in Q4 2020.
• Average Income from Discontinued Operations over 3 years is $318442.7, with a median of -$73183.0 recorded in 2021.
• The largest YoY upside for Income from Discontinued Operations was 1541.28% in 2021 against a maximum downside of 14.93% in 2021.
• Over 3 years, Income from Discontinued Operations stood at -$189119.0 in 2020, then jumped by 1541.28% to $2.7 million in 2021, then tumbled by 100.04% to -$1163.0 in 2022.
• Per Business Quant data, the three most recent Income from Discontinued Operations figures were -$1163.0 in Q1 2022, $2.7 million in Q4 2021, and -$88872.0 in Q3 2021.